All
Explore Ashland's Latest Innovation - Viatel™ Ultrapure Bioresorbable Polymers
December 11th 2023Ashland has launched Viatel™ ultrapure bioresorbable polymers (lactide / glycolide / caprolactone chemistries), a higher purity platform of controlled release polymers used in long acting injectables and implants (LAII). Ultrapure provides improved release consistency, extended-release durations and are better suited for sensitive drug compounds due to the less acidic micro-environment.
Selecting a CMO Partner for Sterile Injectable Manufacturing (Nov 2023)
November 20th 2023Vetting a CMO for sterile injectable fill finish means more than capacity and equipment. This white paper from Jubilant HollisterStier discusses the range of factors to consider when outsourcing manufacturing for aseptically filled and terminally sterilized products.
Innovative Softgel Technologies to Deliver Poorly Soluble Molecules (Nov 2023)
November 15th 2023In this eBook learn more on how to expedite the development pathway for early phase compounds, and how lipid based formulations provide innovative approach to enhance bioavailability for challenging molecules. It also presents how the lipid-based delivery provides a tool for highly potent, poorly soluble, and unstable APIs.
Softgel Technology for Fast-Tracked Development Programs
November 15th 2023Download the article to learn how lipid-based formulation allows for the timely completion of early and late-phase development activities, and provides relatively straightforward scale-up dosage form manufacturing to meet the commercial volume demand requirements for newly launched products.
Enteric delivery of my API: How to make it right?
November 15th 2023The enteric delivery of pharmaceuticals has long been a challenge for numerous reasons, including protecting the active pharmaceutical ingredients (APIs) from the harsh environment of the gastrointestinal tract and assuring consistent delivery and dosage in the small intestine. This paper reviews the challenges and the science that shows Lonza’s proposed hard capsule solution has been validated to provide acid protection, customization, and scalability.
Exploring Pectin and the Advancement of Delayed Release Technology
November 15th 2023In this webinar, experts will provide an overview of why the properties and structure of pectin are well suited for site-specific delivery to the colon. In addition, experts will also provide insights into how softgel capsules, formed by the combination of both pectin and gelatin, are used in OptiGel® DR, a new delayed release delivery technology for pharmaceutical applications.
Streamline Early-Stage Development to Reach the Clinic Faster
November 6th 2023In this article, gain insights into how early-stage pharmaceutical product development is foundational for successful clinical trials and regulatory approvals, and why collaboration with experienced partners like CDMOs is essential.
Enhancing API Solubility During API Processing and Formulation Development MilliporeSigma
October 26th 2023Understanding the impact of API solubility on the performance of a given drug product and determining ways to enhance dissolution rates is critical to ensuring your product makes it to market, into the hands of patients and clinicians, is well absorbed and provides its intended therapeutic effect. Selecting the best formulation strategy to address challenges for each API, however, can be time-consuming, costly and complex.
Overcoming Obstacles in Gene Therapy Manufacturing
October 26th 2023When it comes to viral vectors, the complexities related to varying serotypes and different sized payloads continue to impact efficiencies and timelines. Hear from Resilience experts on how innovative platform technologies can overcome these challenges and support scalable manufacturing.
Inside Look at Resilience’s Latest Viral Vector Manufacturing Site
October 26th 2023Designed for advanced therapy manufacturing, the Marlborough, MA facility is the first new construction at Resilience. The site will produce, rest, and release viral vector drug substance (DS) and drug product (DP), for clinical and commercial use.
Enhancing API Solubility During API Processing and Formulation Development Merck
October 26th 2023Understanding the impact of API solubility on the performance of a given drug product and determining ways to enhance dissolution rates is critical to ensuring your product makes it to market, into the hands of patients and clinicians, is well absorbed and provides its intended therapeutic effect. Selecting the best formulation strategy to address challenges for each API, however, can be time-consuming, costly and complex.